---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-346919"
form_type: "8-K"
ticker: "KLRA"
cik: "0002096997"
company_name: "Kailera Therapeutics, Inc."
filed_at: "2026-08-12T20:20:55+00:00"
generated_at: "2026-08-12T20:22:09.876469+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kailera Q2 net loss widens to $111.3M; cash $1.17B funds into mid-2028

## Summary
- Net loss $111.3M in Q2 2026 vs $28.9M in Q2 2025; R&D expense $101.1M (up from $19.5M).
- Cash, equivalents and marketable securities $1,171.8M, expected to fund operations into mid-2028.
- Ribupatide oral IND active; global Phase 3 obesity trial initiations planned for H1 2027.
- Phase 2b high-dose ribupatide injection trial fully enrolled (264 pts); data expected mid-2027.
- Appointed Nur Nicholson as CTO and Kathleen Tregoning as Chief Corporate Affairs Officer.

## SEC filing metadata
- accession: 0001193125-26-346919
- form_type: 8-K
- ticker: KLRA
- cik: 0002096997
- company_name: Kailera Therapeutics, Inc.
- filed_at: 2026-08-12T20:20:55+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/0001193125-26-346919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-346919
- JSON: https://secwatch.observer/filing/0001193125-26-346919.json
- Plain text: https://secwatch.observer/filing/0001193125-26-346919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.